Stenotrophomonas maltophilia bacteremia in burn patients
- PMID: 16448762
- DOI: 10.1016/j.burns.2005.08.016
Stenotrophomonas maltophilia bacteremia in burn patients
Abstract
Stenotrophomonas maltophilia has been increasingly reported as a nosocomial opportunistic pathogen in debilitated patients, including burn patients. There is, however, only one published report in English that discusses S. maltophilia bacteremia in burns. We performed a retrospective chart review and statistical analysis of the incidence, the duration of hospital stays before a diagnosis of bacteremia, antimicrobial susceptibility, prognosis, and mortality risk factors in burn patients. From January 1996 to December 2004, 14 episodes of S. maltophilia bacteremia in 13 of 666 patients admitted to the burn center at our hospital were identified. The patients, nine males and four females, ranged in age from 1 to 76 years (mean: 42.9+/-24.4 years). Eleven injuries were from flame burns and two were from scald burns. The mean total burned surface area (TBSA) was 47+/-30.2% and mean prognostic burn index (PBI) was 81.7+/-31.3. The average annual incidence was 2.3 episodes per 1000 admissions, and no outbreak cluster was noticed. The mean hospital stay before bacteremia was 19.8+/-11.9 days. Most isolates were susceptible to ticarcillin-clavulanate (87.5%) and moxalactam (85.7%). The overall mortality was 30.7% (4/13) and correlated significantly with TBSA (P<0.01) and PBI (P<0.05). The incidence of S. maltophilia bacteremia was higher in hospitalized burn patients than in hospitalized non-burn patients. Different antimicrobial susceptibility patterns may exist, especially in different geographic regions. Awareness of the possibility of infection by this opportunistic pathogen and commencement of adequate antibiotics treatment, especially after 3 weeks of intensive care, should be incorporated into the strategy of treatment in major burn patients.
Similar articles
-
[Bacteremia caused by Stenotrophomonas maltophilia: a clinical-epidemiological study and resistance profile].Rev Esp Quimioter. 1998 Sep;11(3):205-15. Rev Esp Quimioter. 1998. PMID: 9795306 Spanish.
-
[Nosocomial Stenotrophomonas maltophilia infections in a university hospital].Mikrobiyol Bul. 2005 Jan;39(1):25-33. Mikrobiyol Bul. 2005. PMID: 15900834 Turkish.
-
Stenotrophomonas (Xanthomonas) maltophilia as an emerging opportunistic pathogen in association with HIV infection: a 10-year surveillance study.Infection. 2003 Jun;31(3):155-61. doi: 10.1007/s15010-003-3113-6. Infection. 2003. PMID: 12789473
-
Endocarditis in burn patients: clinical and diagnostic considerations.Burns. 2008 Aug;34(5):610-6. doi: 10.1016/j.burns.2007.08.002. Epub 2007 Oct 29. Burns. 2008. PMID: 18029099 Review.
-
Stenotrophomonas maltophilia: changing spectrum of a serious bacterial pathogen in patients with cancer.Clin Infect Dis. 2007 Dec 15;45(12):1602-9. doi: 10.1086/522998. Clin Infect Dis. 2007. PMID: 18190323 Review.
Cited by
-
Antimicrobial susceptibility of hospital acquired Stenotrophomonas maltophilia isolate biofilms.Braz J Infect Dis. 2016 Jul-Aug;20(4):365-73. doi: 10.1016/j.bjid.2016.04.002. Epub 2016 May 13. Braz J Infect Dis. 2016. PMID: 27183359 Free PMC article.
-
Immunostimulatory properties of the emerging pathogen Stenotrophomonas maltophilia.Infect Immun. 2007 Apr;75(4):1698-703. doi: 10.1128/IAI.01469-06. Epub 2007 Jan 12. Infect Immun. 2007. PMID: 17220304 Free PMC article.
-
Antibiotic treatment for Stenotrophomonas maltophilia in people with cystic fibrosis.Cochrane Database Syst Rev. 2020 Mar 18;3(3):CD009249. doi: 10.1002/14651858.CD009249.pub5. Cochrane Database Syst Rev. 2020. PMID: 32189337 Free PMC article.
-
Patterns of multidrug resistant organism acquisition in an adult specialist burns service: a retrospective review.Antimicrob Resist Infect Control. 2022 Jun 13;11(1):82. doi: 10.1186/s13756-022-01123-w. Antimicrob Resist Infect Control. 2022. PMID: 35698209 Free PMC article.
-
Global mapping of antibiotic resistance rates among clinical isolates of Stenotrophomonas maltophilia: a systematic review and meta-analysis.Ann Clin Microbiol Antimicrob. 2024 Mar 19;23(1):26. doi: 10.1186/s12941-024-00685-4. Ann Clin Microbiol Antimicrob. 2024. PMID: 38504262 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical